Filter...

AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesInformation ScienceHealth Care

Select a category...

CytarabineAntimetabolitesAntimetabolites, AntineoplasticThioguanineSurgical Sponges6-MercaptopurineMethotrexateVidarabine Phosphate6-AminonicotinamideTetrahydrouridineIdarubicinDaunorubicinTrabeculectomyFluorouracilAntineoplastic Combined Chemotherapy ProtocolsPantothenic AcidLeukemia, Myeloid, AcuteNorleucineDeoxycytidineRemission InductionConsolidation ChemotherapyMitomycinMitoxantroneFloxuridinePhosphonoacetic AcidAzathioprineThymidylate SynthaseArabinonucleosidesAntineoplastic AgentsLeukemia L1210GuanineLeukemia, MyeloidEtoposideDrug SynergismStreptomycesDrug Administration ScheduleTumor Cells, CulturedInduction ChemotherapyNeoplasmsVincristineTreatment OutcomeMeningeal CarcinomatosisPrecursor Cell Lymphoblastic Leukemia-LymphomaInjections, SpinalLeukemic InfiltrationCell SurvivalCytidine MonophosphateCell DivisionAcute DiseaseCarmustineAsparaginaseDrug AgonismApoptosisDisease-Free SurvivalDeoxycytidine KinaseLymphoma, Non-HodgkinLeukemia, Myelomonocytic, AcuteCyclophosphamideArabinonucleotidesLeukemia, Myeloid, Accelerated PhaseSurvival AnalysisRecurrenceCentral Nervous System NeoplasmsAmsacrineSurvival RateSalvage TherapyVidarabineArabinofuranosylcytosine TriphosphateTransplantation, AutologousLeukemia, Myelogenous, Chronic, BCR-ABL PositiveTeniposideAnemia, Refractory, with Excess of BlastsDoxorubicinMyelodysplastic SyndromesDexamethasoneCombined Modality TherapyCell LineLeukemiaMeningitisMelphalanPodophyllotoxinCladribineLeukemia, Myeloid, Chronic-PhaseDrug Resistance, NeoplasmBlast CrisisAdenine NucleotidesInfusions, IntravenousPrednisoneDioxolanesPolyradiculopathyHarringtoninesAclarubicinActuarial AnalysisPrognosisHematopoietic Stem Cell TransplantationCytogenetic AnalysisBurkitt LymphomaMeningesGranulocyte Colony-Stimulating FactorBenzamides

ChemotherapyIntrathecalMethotrexateAnthracyclinesDaunorubicin and cytarabineInhibitsAntineoplastic agentLipidChemotherapeuticIndicationsCytosineGemcitabineDrugsAnti-metaboliteHypersensitivePharmacokineticsToxicityMetabolicAdverseMethodsClassAdultTreatmentTherapyDescriptionPresentTypes

Chemotherapy3

• Background: Toxic erythema of chemotherapy (TEC) describes a spectrum of clinical cutaneous entities occurring after the initiation of cytotoxic chemotherapeutic agents such as antimetabolites (i.e. cytarabine) and anthracyclines (i.e. doxorubicin). (pulsus.com)
• n = 245): intensive chemotherapy, low-dose cytarabine, or best supportive care only. (ox.ac.uk)
• Only physicians experienced in cancer chemotherapy should use Cytarabine Injection. (wikidoc.org)

Intrathecal5

• Intrathecal methotrexate is an antimetabolite that inhibits dihydrofolate reductase, thereby hindering DNA synthesis and cell reproduction in malignant cells. (medscape.com)
• The chemo drugs most often used for intrathecal chemo are methotrexate and cytarabine. (cancer.org)
• After intrathecal administration of the liposomal formulation of cytarabine, drugs levels in plasma are barely detectable, and are unlikely to appear in milk in clinically relevant amounts. (nih.gov)
• DepoCyt ® (cytarabine liposome injection) is indicated for the intrathecal treatment of lymphomatous meningitis. (nih.gov)
• Intrathecal administration of cytarabine injection is indicated for the prophylaxis and treatment of meningeal leukemia . (wikidoc.org)

Methotrexate2

• Of the 387 chemotherapeutic agents reported, the ones most commonly associated with errors were part of the antimetabolite class (40 percent), which includes Methotrexate (15 percent) and Cytarabine (12 percent). (cancer.org)
• Methotrexate is an antimetabolite, which inhibits DHFR resulting in decreased immune function and antineoplastic activity and is FDA approved for psoriasis, RA, and several cancers including choriocarcinoma, AML, lung, head and neck and epidermoid (FDA.gov). (jax.org)

Anthracyclines1

• Daunorubicin is part of a group of drugs called anthracyclines and cytarabine is classified as an antimetabolite. (rxwiki.com)

Daunorubicin and cytarabine14

• Daunorubicin and cytarabine lipid complex is different than other products containing these medications and should not be substituted for one another. (medlineplus.gov)
• Daunorubicin and cytarabine lipid complex slows or stops the growth of cancer cells in your body. (medlineplus.gov)
• Daunorubicin and cytarabine lipid complex comes as a powder to be mixed with liquid and injected intravenously (into a vein) by a doctor or nurse in a medical facility. (medlineplus.gov)
• tell your doctor and pharmacist if you are allergic to daunorubicin, cytarabine, any other medications, or any of the ingredients in daunorubicin and cytarabine lipid complex. (medlineplus.gov)
• Many other medications may also interact with daunorubicin and cytarabine lipid complex, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. (medlineplus.gov)
• You or your partner should not become pregnant while you are receiving daunorubicin and cytarabine lipid complex. (medlineplus.gov)
• You should use birth control to prevent pregnancy in yourself or your partner during your treatment with daunorubicin and cytarabine lipid complex and for 6 months after your final dose. (medlineplus.gov)
• If you become pregnant while receiving daunorubicin and cytarabine lipid complex, call your doctor. (medlineplus.gov)
• Daunorubicin and cytarabine lipid complex may harm the fetus. (medlineplus.gov)
• You should not breastfeed during your treatment with daunorubicin and cytarabine lipid complex and for at least 2 weeks after your final dose. (medlineplus.gov)
• if you are having surgery, including dental surgery, tell the doctor or dentist that you are receiving daunorubicin and cytarabine lipid complex. (medlineplus.gov)
• Daunorubicin and cytarabine lipid complex may cause side effects. (medlineplus.gov)
• daunorubicin and cytarabine . (rxwiki.com)
• 3 mg/m 2 (up to one 4.5 mg vial) on Days 1, 4, and 7 in combination with daunorubicin and cytarabine ( 2.2 ). (nih.gov)

Inhibits6

• Cytarabine is converted intracellularly to the active compound cytarabine-5'-triphosphate, which inhibits DNA polymerase. (medscape.com)
• Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA . (nih.gov)
• It is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. (absource.de)
• Cytosar-U (cytarabine) is a cytidine analog that, when incorporated into DNA, inhibits DNA synthesis and repair ( PMID: 32524309 ). (jax.org)
• One class of drugs that inhibits DNA synthesis is antimetabolites. (microbiologynote.com)
• Cytarabine: This drug inhibits the enzyme ribonucleotide reductase, which is involved in the synthesis of deoxyribonucleotides, the precursors to DNA. (microbiologynote.com)

Antineoplastic agent1

• Cytarabine is an antineoplastic agent that is FDA approved for the treatment of acute non-lymphocytic leukemia of adults and children, acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia . (wikidoc.org)

Lipid2

• Cytarabine lipid complex is used to treat lymphomatous meningitis (a type of cancer in the covering of the spinal cord and brain). (nih.gov)
• The anticancer drug cytarabine formulated inside small particles of a synthetic lipid material called DepoFoam. (seniormag.com)

Chemotherapeutic3

• Published in the July 1, 2007 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study concluded that the antimetabolite class of chemotherapeutic agents are most likely associated with errors, and that errors in drug administration and errors in drug dosing and frequency were the most common mistakes made and consequently, the most potentially harmful. (cancer.org)
• We have demonstrated for the first time that Hmgb1 is an essential activator of cellular response to genotoxic stress caused by chemotherapeutic agents (thiopurines, cytarabine, and 5-fluorouracil), which acts at early steps of antimetabolite-induced stress by stimulating phosphorylation of two DNA damage markers, p53 and H2AX. (aspetjournals.org)
• This finding makes HMGB1 a potential target for modulating activity of chemotherapeutic antimetabolites. (aspetjournals.org)

Indications1

• There is limited information regarding Cytarabine FDA-Labeled Indications and Dosage (Pediatric) in the drug label. (wikidoc.org)

Cytosine1

• Cytarabine is metabolized intracellularly into its active triphosphate form (cytosine arabinoside triphosphate). (pharmacycode.com)

Gemcitabine1

• 5 fluorouracil (5FU), cytarabine and gemcitabine. (buddiesforlife.co.za)

Drugs1

• An anticancer drug that belongs to the family of drugs called antimetabolites. (seniormag.com)

Anti-metabolite1

• Cytarabine is an antineoplastic anti-metabolite used in the treatment of several forms of leukemia including acute myelogenous leukemia and meningeal leukemia. (pharmacycode.com)

Hypersensitive2

• Hypersensitive to cytarabine or any component of the formulation with active meningeal infection. (nih.gov)
• Cytarabine is contraindicated in those patients who are hypersensitive to the drug. (wikidoc.org)

Pharmacokinetics2

• Hamada A, Kawaguchi T, Nakano M. Clinical pharmacokinetics of cytarabine formulations. (nih.gov)
• View DBL Cytarabine mechanism of action for pharmacodynamics and pharmacokinetics details. (azurewebsites.net)

Toxicity1

• We investigated the influence of polymorphisms in the methylene tetrahydrofolate reductase (MTHFR) gene and coadministration of antimetabolites on post-HDMTX toxicity. (nih.gov)

Metabolic1

• Therefore, we conducted an association study between the adverse reactions to cytarabine therapy and single nucleotide polymorphisms (SNPs) in cytarabine metabolic genes. (tokushima-u.ac.jp)

Adverse1

• This, coupled with the information that patients with a defective enzyme in breaking down 6-MP had a higher propensity in developing secondary brain tumors (43% versus 8% at 8 years), leads one to believe that the intensification of antimetabolite therapy plays a very large role in the adverse outcomes described in this paper. (oncolink.org)

Methods1

• Methods: Among the patients treated with cytarabine at the Department of Hematology at Tokushima University Hospital, 46 patients provided informed consent and were included in this study. (tokushima-u.ac.jp)

Class2

• Cytarabine is in a class of medications called antimetabolites. (medlineplus.gov)
• Belongs to the class of antimetabolites, pyrimidine analogues. (azurewebsites.net)

Adult2

• There is limited information regarding Off-Label Guideline-Supported Use of Cytarabine in adult patients. (wikidoc.org)
• There is limited information regarding Off-Label Non-Guideline-Supported Use of Cytarabine in adult patients. (wikidoc.org)

Treatment1

• Cytarabine is a pyrimidine nucleoside analog that is used mainly in the treatment of leukemia. (absource.de)

Therapy2

• However, one must incorporate antimetabolite systemic therapy into the picture. (oncolink.org)
• The physician must judge possible benefit to the patient against known toxic effects of this drug in considering the advisability of therapy with cytarabine. (wikidoc.org)

Description1

• View DBL Cytarabine description for details of the chemical structure and excipients (inactive components). (azurewebsites.net)

Present1

• However, after 3 weeks of abstinence from breastfeeding, it is unlikely that cytarabine was present in milk during breastfeeding. (nih.gov)

Types1

• cytarabine decreases effects of adenovirus types 4 and 7 live, oral by pharmacodynamic antagonism. (medscape.com)